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Abstract Aminopeptidase P (AP-P), purified to homogeneity 
from porcine kidney membranes, was completely inactivated by 
treatment with 0.2 mM diethylpyrocarbonate (DEP) at pH 7.0. 
Treatment of the modified enzyme with 20 mM hydroxylamine 
resulted in recovery of AP-P activity. The differential absorption 
of native and modified AP-P at 240 nm showed that DEP 
modified two histidyl residues per mol of AP-P. The substrates, 
bradykinin(1-5) and Gly-Pro-Hyp, and also the inhibitor, 
apstatin, could protect against DEP inactivation. These results 
suggest hat histidine residues are critical for AP-P activity. 
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1. Introduction 
Aminopeptidase P (AP-P; EC 3.4.11.9) is a zinc-metallo- 
peptidase [1] that can catalyse the release of N-terminal amino 
acid residues from peptides where a proline residue is present 
in the penultimate position [2]. AP-P was first suggested to 
have a role in the degradation of collagen [2] but has subse- 
quently been reported to be involved in pulmonary bradykinin 
metabolism [3,4]. The enzyme may also play a role in the 
metabolism of certain other bioactive peptides uch as sub- 
stance P, peptide YY and neuropeptide Y [3,5,6]. AP-P is 
located in the microvillar membranes of pig and human kid- 
ney [1], and has also been found in rat intestine [7] and lung 
[8], bovine lung [3], and guinea pig serum and kidney [9]. A 
soluble (cytosolic) form of AP-P has been identified in rat 
brain [10] but this may represent a distinct gene product 
from membrane AP-P. 
We have previously identified AP-P as a cell-surface ectoen- 
zyme anchored to the membrane by a glycosylphosphatidyl 
inositol (GPI) moiety [11] and exploited the selective release of 
AP-P by bacterial phosphatidylinositol-specific phospholipase 
C in the purification of the enzyme from porcine kidney mem- 
branes [1]. During the initial purification of AP-P from pig 
kidney, it was observed that Mn 2÷ ions were required for 
optimal activity of the enzyme [2]. Further work has shown 
that both Mn 2+ and Co ~+ ions stimulate the activity of pig 
AP-P, whereas ome other bivalent cations were inhibitory. 
These results, together with the inhibition of AP-P activity 
by chelating agents uch as EDTA and 1,10-phenanthroline 
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[1], have confirmed the earlier observations by several groups 
that AP-P is a metalloenzyme [3,7,12] containing 1 mol of zinc 
per mol of protein [13]. 
Unlike other brush border aminopeptidases (e.g. AP-N, 
AP-A, AP-W), AP-P is not inhibited by actinonin, amastatin, 
puromycin or bestatin [1] but a specific inhibitor of AP-P, 
apstatin, has recently been developed [8,14]. Rather than re- 
sembling aminopeptidases N, A and W, AP-P appears to be 
related to the recently described proline peptidase family of 
hydrolytic enzymes which includes E. co//aminopeptidase P, 
prolidase, methionine aminopeptidase and creatinase [15,16]. 
The amino acid sequence of pig kidney AP-P has recently 
been obtained by Edman degradation and mass spectrometry 
of the purified protein and reveals ome limited sequence si- 
milarities in the C-terminal half of the protein with other 
members of this family [17]. The amino acid sequence of 
AP-P does not contain the typical HExxH motif common to 
many zinc peptidases nor any other recognised zinc-binding 
motif and no residues in the protein important for substrate 
or inhibitor binding, or catalysis, have yet been identified. In 
the present study, therefore, we show that diethylpyrocarbo- 
nate (DEP) inactivates AP-P through the modification of two 
critical histidine residues and substrates and inhibitor can 
protect against such modification. 
2. Materials and methods 
2.1. Materials 
Bradykinin, bradykinin(l 5), bradykinin(2-9), Gly-Pro-Hyp, Pro- 
Hyp and diethylpyrocarbonate (DEP) were purchased from Sigma 
Chemical Co. Ltd., Dorset, UK. The AP-P inhibitor, apstatin 
((2S,3R)-3-amino-2-hydroxy-4-phenylbutanoyl-e-prolyl-e-prolyl-L-ala- 
ninamide), was a generous gift from Professor W.H. Simmons (Loyo- 
la University, Chicago, IL). Bacillus cereus phopholipase C was ob- 
tained from Fluka Chemic AG, Switzerland. Microcentrifuge filters 
(molecular cut-off 30 kDa) were from Sigma. All other chemicals were 
obtained from either BDH Chemicals Ltd. or Sigma Chemical Co. 
Ltd. and were of the appropriate grade. 
2.2. Purification of AP-P from pig kidney 
AP-P was purified by a modification ofthe method of Hooper et al. 
[1]. Pig kidney cortex (200 g) was homogenised in 0.33 M sucrose, 50 
mM Tris-HC1 buffer, pH 7.4 to a total volume of 1500 ml and cen- 
trifuged at 8000xg for 15 min. The supernatant was centrifuged at
26,000 xg for 2 h and then the pellet was resuspended in 10 mM Tris- 
HC1, 0.1 M NaC1, pH 7.4, to 250 ml. After centrifugation at 
31,000xg for 90 rain, the membrane pellet was resuspended in 10 
mM Tris-HC1, 0.1 M NaC1, pH 7.4, to give a protein concentration 
of approx. 7.5 mg/ml and incubated with Bacillus cereus PLC (0.35 
units/mg of protein) for 2 h at 37°C. After centrifugation at 31,000 x g 
for 90 min, the supernatant was dialysed extensively against 50 mM 
Tris-HCl, pH 8.0. The dialysed supernatant was then subjected to 
sequential chromatography oncilastatin-Sepharose, DEAE-cellulose, 
Mono-Q and alkyl-Superose as in [1] except that elution from Mono- 
Q was performed first isocratically with 10 mM Tris-HC1, 0.I M KC1, 
pH 8.0, and then followed by a linear gradient to 0.5 M KC1 in order 
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Fig. 1. The effect of DEP on AP-P activity. AP-P was reacted with 
various concentrations of DEP (0, 0.02, 0.04, 0.08, 0.2 mM) in 0.1 
M phosphate buffer, pH 7.0, at room temperature for 30 min. 
Then, the activity of AP-P was assayed with Gly-Pro-Hyp or brady- 
kinin as substrate. The reactivation experiment was performed with 
20 mM hydroxylamine at 4°C for 4 h. Gly-Pro Hyp ((3), bradykinin 
(zx), reversal with hydroxylamine ( ). 
to remove impurities more effectively. The final product was appar- 
ently homogeneous (Mr 91,000) as assessed by SDS-PAGE. 
2.3. Assay of AP-P 
The hydrolysis of Gly-Pro-Hyp (1 mM) by AP-P was assayed by an 
HPLC method, as described previously [1]. Preincubation of enzyme 
sample in 0.1 M Tris-HC1, pH 8.0 containing 4 mM MnCI2 for 5 min 
was followed by a 30 rain incubation with substrate (100 ~tl total 
volume), all at 37°C. The reaction was terminated by boiling for 
4 min. Under these conditions the formation of product (Pro-Hyp) 
was linear with time. Hydrolysis of Gly-Pro-Hyp was monitored using 
reverse-phase HPLC [1]. The product, Pro-Hyp, was quantified by 
calibration from a standard curve. 
Hydrolysis of bradykinin by AP-P was also monitored by reverse- 
phase HPLC using a 20 min linear gradient of 4-45% (v/v) acetonitrile 
in 0.08% H3PO4, followed by 5 rain elution at final conditions. The 
product, bradykinin(2~), was quantified by calibration from standard 
curves .  
2.4. Chemical modification ofAP-P with DEP 
AP-P was incubated in 0.1 M phosphate buffer, pH 7.0, at room 
temperature with various concentrations of DEP for 30 rnin before 
enzyme activity was measured. To confirm whether the modified reac- 
tion could be reversed, excess DEP was removed using a microcen- 
trifuge filter. Then, the samples were reacted with 20 mM hydroxyla- 
mine at 4°C for 4 h after which AP-P activity was assayed. 
2.5. Spectroscopic studies 
The differential spectra of carbethoxylated against untreated en- 
zyme were obtained on a Uvikon 930 spectrophotometer. Spectro- 
scopic studies in the range 220-300 nm were performed at room 
temperature in 0.1 M phosphate, pH 7.0, with DEP at 0.2 mM and 
AP-P at 10 laM. The number of modified histidine residues was cal- 
culated by using 3200 M-l'cm -1 at 240 nm as the molar extinction 
coefficient for N-carbethoxyhistidine residues [18]. 
2.6. Protection of AP-P against DEP inactivation 
AP-P was preincubated with various substrates or inhibitors, and 
then incubated with 0.08 mM DEP at room temperature for 30 min. 
After removal of excess reagents and products, the residual enzyme 
activity of each sample was assayed. 
3. Results 
3.1. Inactivation of AP-P by modification with DEP 
Purified AP-P (4 ~tM) from pig kidney was reacted with 
various concentrations of DEP (0, 0.02, 0.04, 0.08, 0.2 mM) 
in 0.1 M phosphate buffer, pH 7.0, for 30 min. After treat- 
ment, AP-P activity was assayed with both Gly-Pro-Hyp or 
bradykinin as substrate. At 0.2 mM DEP, the activity of AP-P 
was completely abolished when measured with either substrate 
(Fig. 1). Treatment of DEP-inactivated AP-P with 20 mM 
NH~OH restored a major part of the original activity (Fig. 1). 
3.2. Stoichiometry of DEP modification of AP-P 
AP-P (10 ~M) was treated with 0.2 mM and 5 mM DEP for 
30 min and the UV absorption difference spectrum of DEP- 
treated against untreated-enzyme, in the range of 220-300 nm, 
was obtained for both concentrations. An absorption maxi- 
mum in the difference spectrum was seen in the region of 240 
nm and there was no decrease in absorbance around 280 nm 
(Fig. 2). The increase in absorption at 240 nm in 0.2 mM DEP 
corresponded to the modification of 2.3+0.2 histidine residues 
per mol of the enzyme (mean+range of two observations). 
Under these conditions approx 80% of the AP-P activity 
was inhibited. To establish whether DEP could modify addi- 
tional histidine or tyrosine residues at higher concentrations, 
AP-P was reacted with 5 mM DEP under the same conditions 
as before. The absorbance increase between 220 nm and 230 
nm showed excess DEP could react further with histidine 
residues forming di-N-carbethoxyhistidine d rivatives (Fig. 
2). The decrease in absorption at 280 nm also indicated O- 
carbethoxytyrosyl residues could be formed under conditions 
of excess DEP (Fig. 2). At 5 mM DEP the estimated number 
of modified histidyl residues per mol of AP-P was 8. 
The effect of N-acetyl imidazole on AP-P activity was also 
investigated, which is known as a specific modifying reagent 
for tyrosyl residues [20]. At 0.5 mM N-acetyl imidazole, the 
activity of AP-P was not affected (relative activ- 
ity = 101.2 + 11.1%). 
3.3. Protection of AP-P against DEP inactivation 
AP-P (4 ~tM) was preincubated with 0.5 mM bradykinin(1- 
5), 1 mM Gly-Pro-Hyp or 0.05 mM apstatin in 0.1 M phos- 
phate buffer, pH 7.0, at 37°C for 5 min and then reacted with 
0.08 mM DEP at room temperature for 30 min. After excess 
reagents and products were removed by microcentrifuge filter, 
the activity of the enzyme was assayed. Both substrates, bra- 
dykinin(1-5) and Gly-Pro-Hyp, and the inhibitor, apstatin, 
were able to protect against DEP inactivation (Table 1). 
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Fig. 2. Ultraviolet difference spectra of AP-P with DEP. This spec- 
troscopic study was performed at room temperature in 0.1 M phos- 
phate buffer, pH 7.0, with DEP at 0.2 mM (solid line) and 5 mM 
(broken line). The absorbance shown has been computer-corrected 
for the blank (enzyme in buffer with same volume of ethanol) in the 
range of 220-300 nm. 
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Table 1 
Protection of AP-P against inactivation by DEP 
Protecting agent Relative activity 
(%) 
None 33.8 + 3.6 (3) 
Bradykinin(l-5) (0.5 mM) 84.8 + 1.6 (3) 
Gly-Pro-Hyp (1 mM) 92.2 + 2.7 (3) 
Apstatin (0.05 mM) 79.8 + 5.5 (3) 
AP-P was preincubated with substrates or inhibitor, and then incu- 
bated with 0.08 mM DEP at room temperature for 30 min. After 
removal of excess reagents and products, the residual enzyme activ- 
ity of each sample was determined with Gly-Pro-Hyp as a substrate. 
Activity is quoted relative to the activity of an untreated sample of 
enzyme (100% activity =75.3 nmol/min/mg). 
4. Discussion 
The primary effect of low concentrations of DEP on pro- 
teins is the modification of histidyl residues. However, under 
certain conditions, DEP can also react with tyrosyl and lysyl 
residues. These various reactions can be distinguished 
spectrophotometrically. O-Carbethoxylation f a tyrosyl resi- 
due is readily detected by a decrease in absorbance at280 nm 
whereas mono-N-carbethoxylation of a histidyl residue shows 
an absorption maximum between 230 and 250 nm. Modifica- 
tion of lysyl residues with DEP cannot be reversed by hydro- 
xylamine. Also, hydroxylamine at 20 mM can decarbethoxy- 
late selectively histidyl residues under conditions that do not 
decarbethoxylate 2-O-carbethoxy t rosyl residues [19]. In the 
present work, AP-P was completely inactivated at 0.2 mM 
DEP and could be reactivated by treatment with 20 mM 
NH2OH, implicating specific modification of histidyl residues. 
Under these conditions, the number of histidine residues mod- 
ified, estimated by measuring absorbance difference at 240 
nm, was 2.3. 
Excess DEP was observed to react with a further six histidy! 
residues and also to form di-N-carbethoxyhistidine deriva- 
tives, which absorb maximally between 220 and 230 nm. For- 
mation of O-carbethoxytyrosyl residues was also detected. 
The use of excess DEP may lead to inaccurate quantification 
and irreversible modification of enzyme action. It is therefore 
important to establish the lowest concentrations of DEP re- 
quired for modification, in this case 0.2 mM. At this concen- 
tration, spectroscopic studies revealed no decrease in absor- 
bance at 280 nm. The lack of effect of N-acetyl imidazole also 
confirmed that tyrosine is not involved in the activity of AP-P. 
Protection of enzymic activity from an external inactivating 
reagent by substrates, products, or competitive inhibitors is 
generally regarded as evidence that the target residues for 
that reagent reside within the active site. The presence of 
substrates, bradykinin(1-5) and Gly-Pro-Hyp, and the inhibi- 
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tor, apstatin, protected against DEP inactivation implying 
that at least 2 of the 13 histidine residues in AP-P are impor- 
tant for substrate and inhibitor binding, or catalytic activity. 
Sequence similarities with other members of the proline 
peptidase family [17] are restricted to the C-terminal half of 
AP-P (residues 350-623), suggesting that the active site of the 
enzyme resides in this part of the protein. In this region there 
are seven histidines but only four of these (residues 403, 493, 
497 and 506) align with other members of the proline pepti- 
dase family, cDNA cloning of AP-P coupled with site-directed 
mutagenesis will be required to identify the critical histidine 
residues unequivocally and provide insight into the chemical 
mechanisms underlying this new class of proteolytic enzymes. 
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